论文部分内容阅读
目的:观察通心络胶囊治疗慢性收缩性心力衰竭(CHF)的临床疗效。方法:将70例CHF患者随机分为2组,对照组34例予常规抗心力衰竭(强心、利尿、血管紧张素转换酶抑制剂及去除病因等)治疗,治疗组36例在对照组治疗基础上加用通心络胶囊。2组疗程均为3月。观察并详细记录患者治疗前后症状、体征、血压、心功能分级,对患者进行彩色多普勒超声心动图测量:左室收缩末期容积(LVESV)及左室舒张末期容积(LVEDV)、左室射血分数(LVEF)、短轴缩短率(FS)、心排血量(CO)、心排指数(CI)等指标。结果:治疗组总有效率为91.7%,高于对照组的76.5%,差异有显著性意义(P<0.05)。治疗组治疗后LVEDV和LVESV均缩小,LVEF、CO、CI和FS改善,与治疗前比较,差异均有非常显著性意义(P<0.01);对照组治疗后LVEDV、LVESV均缩小,LVEF、FS亦改善,与治疗前比较,差异有显著性或非常显著性意义(P<0.05,P<0.01);2组治疗后各指标比较,差异也有显著性意义(P<0.05),治疗组疗效优于对照组。2组收缩压(SBP)、舒张压(DBP)、心率均改善(P<0.05),治疗组降低血压、减慢心率效果优于对照组(P<0.05)。结论:通心络胶囊治疗CHF疗效确定。
Objective: To observe the clinical effect of Tongxinluo Capsule in the treatment of chronic systolic heart failure (CHF). Methods: Seventy patients with CHF were randomly divided into two groups. The control group was given conventional anti-heart failure (cardiac, diuretic, angiotensin converting enzyme inhibitor and etiologic agent), 34 in the control group were treated in the control group Based on the use of Tongxinluo capsule. The two groups were treated in March. The symptoms, signs, blood pressure and heart function before and after treatment were observed and recorded. Color Doppler echocardiography was used to measure the left ventricular end-systolic volume (LVESV) and left ventricular end-diastolic volume (LVEDV) (LVEF), short axis shortening (FS), cardiac output (CO), cardiac index (CI) and other indicators. Results: The total effective rate of the treatment group was 91.7%, which was higher than 76.5% of the control group, the difference was significant (P <0.05). After treatment, LVEDV and LVESV were both reduced, LVEF, CO, CI and FS were improved in the treatment group compared with those before treatment (all P <0.01); LVEDV and LVESV in the control group were reduced, LVEF, FS (P <0.05, P <0.01). There was also a significant difference between the two groups after treatment (P <0.05), and the therapeutic effect was better in the treatment group than in the control group In the control group. The systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate were improved in the two groups (P <0.05). The blood pressure and heart rate in the treatment group were better than those in the control group (P <0.05). Conclusion: Therapeutic effect of Tongxinluo capsule on CHF.